- Long-term safety of risankizumab2020 | First Faculty of Medicine, Third Faculty of Medicine
- Risankizumab in first-line treatment of psoriasis2022 | Faculty of Medicine in Pilsen
- A case of psoriasis treated with risankizumab at the time of the COVID-19 epidemic2020 | Faculty of Medicine in Hradec Králové
- New treatment options for psoriasis based on new findings in the pathogenesis of psoriasis - risankizumab2020 | Faculty of Medicine in Pilsen
- Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial2020 | Faculty of Medicine in Pilsen
- Risankizumab in treatment of psoriatic arthritis2023 | First Faculty of Medicine
- Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal2019 | Faculty of Medicine in Pilsen
- Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (Clinical trial IMMerge)2020 | Faculty of Medicine in Pilsen
- Risankizumab2019 | Third Faculty of Medicine
- Coexistence of palmoplantar pustulosis and ichthyosis vulgaris treated by risankizumab2021 | Third Faculty of Medicine
- Risankizumab v léčbě psoriatické artritidy2023 | First Faculty of Medicine
- Acrodermatitis continua Hallopeau successfully treated by risankizumab2021 | Third Faculty of Medicine
- Successful treatment of refractory extensive pityriasis rubra pilaris with risankizumab2021 | Faculty of Medicine in Pilsen
- Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic2021 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine, Central Library of Charles University
- Successful treatment of psoriasis with risankizumab in an HIV positive patient with sexually transmitted infection comorbidities2022 | First Faculty of Medicine, Second Faculty of Medicine
- Úspěšná léčba psoriázy risankizumabem u HIV pozitivního pacienta2022 | First Faculty of Medicine, Second Faculty of Medicine
- Nová biologická léčba psoriázy: risankizumab - první klinické zkušenosti2020 | Third Faculty of Medicine
- Léčba risankizumabem u dvou pacientů s těžkou psoriázou po switchi z jiné biologické terapie2021 | Third Faculty of Medicine
- Zkušenosti s risankizumabem v léčbě středně těžké až těžké psoriázy v běžné klinické praxi2021 | Third Faculty of Medicine
- Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti-tumour necrosis factor alpha2021 | Third Faculty of Medicine
- 1 Nehtová psoriáza léčená risankizumabem2021 | Third Faculty of Medicine
- 9 Úspěšná léčba risankizumabem u pacientky s hidradenitis suppurativa a s roztroušenou sklerózou2021 | Third Faculty of Medicine
- Current Approach to Modern Treatment of Psoriasis - Updated Guidelines of ČDS JEP for Targeted Treatment of Severe Chronic Psoriasis2019 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine
- Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study2021 | Third Faculty of Medicine
- Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study2022 | Third Faculty of Medicine